Tuesday, June 23, 2026

Europe risks a crisis if it fails to halt pollinator loss, researchers warn



Eight EU-funded research consortia warn that Europe risks a crisis if it fails to halt pollinator loss. Their solution: a roadmap to reverse wild pollinator decline and protect managed bees.




The University of Bergen

Privet Hawk-moth 

image: 

The Privet Hawk-moth is a night-active pollinating moth found in Europe and parts of Asia.

view more 

Credit: Jeff Ollerton






Eight EU-funded research consortia warn that Europe risks a crisis if it fails to halt pollinator loss. Their solution: a roadmap to reverse wild pollinator decline and protect managed bees.

A new White Paper from eight major EU-funded pollinator projects warns that the resilience of Europe’s vital societal functions and food security are at stake if the EU fails to halt and reverse wild pollinator declines, and to support managed pollinators. Behind the report is an interdisciplinary team of 135 leading researchers with expertise ranging from ecosystem ecology, pollinator ecology, ecological economics, social science, environmental history, behavioural psychology, political science, and environmental law. The report flags the EU’s siloed governance structures and resulting policy incoherence as the major barrier to pollinator restoration. It states that the EU and its Member States urgently need to act by making Pollinator Stewardship an explicit and measurable top-priority across policies on agriculture, environment, chemicals, research and innovation, trade, finance, planning, legislation, and education.

The report diagnoses the looming pollinator crisis as arising from a dysfunctional relationship between humans and nature. Seeing humans as separate from and superior to nature, and thinking of nature as an object for human use as a resource, reinforces institutional structures that exploit nature for short-term individual and material gain. This leads to unsustainable agricultural practices that risk jeopardising the resilience of the ecosystems on which humanity critically depends.

There is more at stake than food security, the report warns. Indeed, many of Europe's economic supply chains and sectors depend on pollination of flowering plants. Think of medicinal plants, food supplements, biomass energy crops, biomaterials, textiles, fodder, cosmetics, decoration, art, culture, and tourism.

The report also highlights the low pollinator literacy of key societal actors whose daily actions can make the difference for pollinators. It advocates mandating ecoliteracy in the education of professionals in all key sectors that affect pollinators and their habitats.

According to the report’s lead author, Professor Jeroen van der Sluijs, many people whose actions affect pollinators and their habitat are already doing their best to help save the bees. But most lack the literacy to understand how their practices cascade into pollinator loss. “Many farmers plant wildflower strips along their fields, but almost no one knows that some moths are more effective pollinators than honeybees. These little creatures of the night, clothed in velvet and moonlit dust, need host plants for their larvae, not only flowers. Host plants for pollinating hoverflies, beetles and moths are missing in most seed-mixtures for flower strips.”

Avoiding a scenario in which Europe is hit by a pollination crisis requires addressing the EU’s functioning and moving away from its siloed governance structures. This requires addressing fragmented responsibilities across sectors, top-down policy design, and weak coordination among administrations that currently hinders effective pollinator restoration. According to the authors, the conflict between short-term production goals and the need to maintain pollination services as a public good must be solved as soon as possible.

The report ends with a detailed roadmap of 15 urgent, evidence-informed recommendations for action that, when fully implemented, can reverse pollinator decline in Europe.

Full White Paper:

https://zenodo.org/records/20715669

 

Boom in ketamine clinics and at-home delivery sparks safety concerns




Anesthesiologists call for stronger oversight





American Society of Anesthesiologists






Key Takeaways:

  • Anesthesiologists are urging lawmakers and regulators to act on ketamine use that occurs without consistent medical oversight. Texas is among the states proposing stricter regulations.
  • The boom in the U.S. ketamine market — projected to reach more than $14 billion by 2035 — results from the surge in clinics and at-home telehealth prescribing and delivery for mental health conditions.
  • Ketamine can cause serious risks — including breathing problems, blood pressure and heart rate instability and potential misuse — and should only be administered with appropriate monitoring and trained medical supervision.

CHICAGO — The American Society of Anesthesiologists is calling on policymakers to address the fast-growing problem of home delivery of ketamine and the lack of physician oversight in ketamine clinics.

As the U.S. ketamine market surpasses $5 billion, the rapid boom in clinics and at-home telehealth prescribing is alarming anesthesiologists who warn that access to the powerful anesthetic is expanding faster than patient safety standards. The market is projected to nearly triple in the next decade, prompting calls for stronger safeguards and broader regulatory action.

Used in hospitals for anesthesia and sedation, ketamine is increasingly prescribed off-label for mental health conditions. Existing literature suggests that the drug can benefit patients, including Veterans, with conditions such as depression and post-traumatic stress disorder. However, in some cases, ketamine is prescribed remotely and delivered to patients’ homes —without an in-person evaluation or direct medical supervision.

The risks are not theoretical. Last year, a 41-year-old New York woman seeking relief from depression died after being prescribed at-home ketamine through a telehealth company — even though she had reported taking Xanax, a combination the FDA warns can lead to fatal breathing problems.

ASA is urging policymakers and medical experts to scrutinize this trend and work to advance proposals to strengthen patient protections.

The Texas Medical Board recently proposed rules to regulate the administration of ketamine in medical facilities and clinics and require greater oversight during treatment. ASA submitted a comment letter emphasizing that ketamine administration should occur under the direct supervision of a qualified physician who is immediately available for in-person evaluation and intervention. Rather than endorsing Texas’ proposed rules, ASA urged stronger safeguards. Bills to strengthen patient protections have been introduced in Georgia, Missouri and Utah.

“We have grave concerns about the home delivery and use of ketamine,” said ASA President Patrick Giam, M.D., FASA. “You can move very quickly from feeling relaxed to becoming deeply sedated, and without proper monitoring and supervision, this can become dangerous. I’m concerned that without stronger regulation, we risk repeating another opioid-like public health crisis, particularly because many people underestimate the potential dangers of ketamine.”

Anesthesiologists note three key safety concerns that require close medical supervision:

  • Breathing complications: Ketamine can slow or stop breathing, especially at higher doses or when combined with other medications.
  • Heart and blood pressure instability: The drug can cause sudden and dangerous increases in blood pressure and heart rate.
  • Risk of misuse and diversion: Without proper safeguards, ketamine may be misused, shared, illegally resold or combined with other substances, increasing the risk of harm.

In hospitals and accredited medical facilities, ketamine is administered with continuous monitoring and immediate access to emergency care. These safeguards — including trained personnel to manage airway or cardiovascular emergencies — may not be available in all outpatient settings and are typically not available at home.

“You can go from a short online screening to receiving a powerful anesthetic at home,” said Dr. Giam. “If something goes wrong, there may be no one there trained to respond. In the hospital, we have strict protocols to account for every milligram of ketamine administered, yet ketamine used at home is subject to far less scrutiny.”

In guidance updated this month, ASA emphasizes that ketamine used for non-anesthetic purposes should meet the same safety standards as other anesthetic drugs, including appropriate patient selection, monitoring and physician oversight.

Patients considering ketamine therapy for mental health conditions should talk with their physician and ask how the drug will be administered, who will monitor them and what safety protocols are in place in case of an emergency.

 

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS
Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 60,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during, and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about how anesthesiologists help ensure patient safety, visit asahq.org/madeforthismoment. Follow ASA on Facebook, X, Instagram, Bluesky, and LinkedIn.

 

# # #

 

Injectable hydrogel made from silk and kudzu plant compound achieves complete wound closure in laboratory tests





Terasaki Institute for Biomedical Innovation

Injectable Hydrogel Made from Silk and Kudzu Plant Compound Achieves Complete Wound Closure in Laboratory Tests 

image: 

{Left to Right} David Hubbard (Research Associate), Saeed Safari (Bioprocessing Associate I), Dr. Menekse Ermis Sen (Terasaki Fellow), Dr. Eliana Duek (Visiting Scholar), Dr. Bruna V. Quevedo (Visiting Scholar).

view more 

Credit: Terasaki Institute for Biomedical Innovation






Los Angeles, CA – June 22, 2026 - Researchers at the Terasaki Institute for Biomedical Innovation have developed an injectable hydrogel, a water-based gel material, made from silk proteins and a plant-derived compound. In laboratory tests, the material promoted complete wound closure within 72 hours, suggesting a potential new approach to minimally invasive soft tissue repair. 

Wounds that are difficult to reach or slow to heal present a persistent challenge in medicine. Current biomaterials, materials engineered to interact with biological systems, often require surgery to implant, lack the mechanical flexibility needed to conform to soft tissue, or fail to support robust cell growth. The new material combines two naturally occurring substances. The first is silk fibroin (SF), a protein from silkworm cocoons that is well-tolerated by the body. The second is puerarin (PUE), a bioactive compound from the root of the kudzu plant with anti-inflammatory and antioxidant properties. 

The team systematically tested five formulations containing increasing amounts of puerarin, ranging from 1 to 5%, combined with a fixed concentration of silk fibroin. Published in ACS Omega, the study found that puerarin strengthened the hydrogel network through hydrogen bonding, a type of physical attraction between molecules. Importantly, this process did not alter the underlying protein structure of silk fibroin. Higher puerarin concentrations produced denser internal networks and increased mechanical stability. The material could also flow through a fine 27-gauge needle under pressure and recover its gel-like structure once injected. 

In laboratory studies, human skin cells exposed to the hydrogels showed cell viability above 95% from day one. Cells cultured with the material achieved complete wound closure within 72 hours across all formulations tested. The highest puerarin concentration showed approximately 60% wound closure within the first 24 hours alone. No signs of toxicity were observed in any tested formulation. 

“What excited us most was seeing complete wound closure in all formulations by 72 hours. That result, combined with the material’s ability to be injected through a fine needle, suggests real clinical relevance for soft tissue applications,” said Dr. Bruna V. Quevedo, Visiting Scholar at the Terasaki Institute and first author of the publication. 

“Injectable biomaterials that can be delivered through a small needle and still support tissue repair have the potential to reduce the burden of invasive procedures for patients. This work brings us a step closer to that goal,” said Dr. Menekse Ermis Sen, Terasaki Fellow at the Terasaki Institute for Biomedical Innovation. 

This research could support the development of minimally invasive treatments for soft tissue injuries and chronic wounds. Further studies in animal models are needed to validate the material’s performance under real physiological conditions. 

For more information, please contact: 
Dr. Menekse Ermis Sen, Terasaki Fellow 
Terasaki Institute for Biomedical Innovation 
Email: mermis@terasaki.org  

About the Terasaki Institute for Biomedical Innovation 
The Terasaki Institute for Biomedical Innovation is a non-profit research organization that invents and fosters practical solutions that restore or enhance the health of individuals. The Institute aims to enhance the quality of human life through translational research and the acceleration of biomedical innovation. TIBI's research focuses on the development of biomaterials, cellular and tissue engineering, medical devices, and microfluidic systems. 

 
### 

 

Study finds prostate cancer screening discussions are rare – but make a big difference




Medical University of South Carolina
Nicholas Shungu, M.D. 

image: 

Family medicine physician Nicholas Shungu, M.D., has found that prostate cancer screening often isn't discussed in primary care visits.

view more 

Credit: Medical University of South Carolina






Millions of men face a decision about whether to be screened for prostate cancer. National guidelines say that decision should begin with a conversation about the risks and benefits of testing.

But a new MUSC study suggests those conversations may not be happening nearly as often as they should. Researchers found that discussions about prostate cancer screening were documented in only a small fraction of primary care visits. Yet when those conversations did occur, men were far more likely to get screened.

The research, published in the Southern Medical Journal and led by Nicholas Shungu, M.D., a family medicine physician at MUSC Health and researcher at MUSC Hollings Cancer Center, underscores a gap between national guidelines and clinical practice.

"One of the biggest takeaways was the surprisingly low rate of documented shared decision-making conversations," said Shungu. "The other key finding was that when those conversations were documented, screening was much more likely to occur."

A different approach to cancer screening

Unlike mammograms or colonoscopies, prostate cancer screening is not universally recommended once men reach a certain age. Instead, the U.S. Preventive Services Task Force, American Cancer Society and other medical organizations recommend that men discuss screening with their clinicians and make an informed decision based on their personal risks and preferences.

That recommendation reflects the complex history of prostate cancer screening.

The prostate-specific antigen, or PSA, blood test can detect prostate cancer early and has been shown to reduce deaths from the disease. However, the test is not perfect. As men age, the prostate naturally enlarges and produces more PSA, which can raise blood test levels even when cancer is not present. Because the PSA test cannot determine why levels are elevated, some men without cancer may undergo unnecessary biopsies. At the same time, many prostate cancers grow slowly and may never cause symptoms or become life-threatening, raising concerns about overtreatment. These factors have shaped the ongoing discussion around prostate cancer screening.

Historically, those concerns led experts to question whether the benefits of screening outweighed the risks. But Shungu said the landscape has changed dramatically in recent years.

New tools such as prostate MRI can help doctors to determine which patients need additional testing, while many low-risk cancers can be safely monitored through active surveillance. Those advances, he said, have reduced some of the concerns that originally fueled resistance to widespread screening.

"We've moved away from the idea that everyone should automatically be screened or not be screened," he said. "The recommendation now is that patients and clinicians have a discussion and decide together what's right for that individual."

As screening and treatment options have become more sophisticated, Shungu said that conversations between patients and clinicians have become even more important.

Looking at what happens in practice

To determine whether those conversations were taking place, the researchers reviewed the medical records of 600 men ages 45 to 69 who received care at MUSC family medicine clinics between 2019 and 2020.

"Different guideline organizations recommend slightly different ages to start screening discussions, particularly for higher-risk groups such as Black men," Shungu said. "We wanted to be fairly broad in who we included so we could capture the population for whom these conversations should be taking place."

This study builds on Shungu's previous research by examining what happens during real-world clinical encounters. The researchers examined whether clinicians documented shared decision-making conversations about prostate cancer screening in patients’ medical records and whether those patients went on to receive PSA testing.

The results revealed a substantial gap between guideline recommendations and clinical practice. Overall, conversations about prostate cancer screening were uncommon, with only 6% of patients having a documented discussion. Documentation rates did not differ significantly by race, age, insurance status or family history of cancer.

One important caveat is that some discussions may have occurred without being documented in the medical record.

"With any chart review study, there's always the possibility that clinicians had the conversation but didn't document it," Shungu said. "Even with that limitation, though, the numbers were surprisingly low."

Conversations linked to higher screening rates

Although the conversations themselves were uncommon, their impact was striking.

Among men with documented shared decision-making discussions, nearly 72% went on to receive a screening PSA test. Among those without a documented conversation, only about 36% received screening.

The association was even stronger among Black men. Eighty-five percent of Black men who had a documented discussion received a screening PSA test, compared with 36% who did not have a conversation. After accounting for other factors, shared decision-making discussions remained one of the strongest predictors of prostate cancer screening.

The finding suggests that shared decision-making does more than help patients to weigh options. For many men, learning about both the benefits and limitations of screening appears to have increased their willingness to be tested.

"When these conversations occurred, most men decided they wanted to be screened," Shungu said. "That tells us these discussions really matter."

Starting the conversation

The findings carry particular importance in South Carolina, where prostate cancer is the most common non-skin cancer in men. South Carolina also has some of the nation's highest prostate cancer mortality rates, raising the need to promote informed screening and early detection. For Shungu, the findings also stand out because of prostate cancer's disproportionate impact on Black men, who are more than twice as likely to die from the disease as men of other races.

Improving awareness and access is already a major focus at Hollings. Through initiatives such as SC AMEN and SC PRENS, Hollings researchers and community partners are working to increase prostate cancer screening and reduce longstanding disparities across South Carolina. The new findings suggest that ensuring men have opportunities to discuss screening with a trusted clinician may be another important step toward that goal.

Shungu hopes the study serves as a reminder for both clinicians and patients. For clinicians, the findings underscore the importance of making time for conversations about prostate cancer screening, even during busy primary care visits. For patients, they highlight the value of asking questions and raising the topic if it is not discussed.

"A lot of people assume that if their doctor doesn't bring up prostate cancer screening, it must not be important. But sometimes there just isn't enough time during a visit,” Shungu said. “Patients are always going to be their own best advocates and should feel empowered to ask about it and make sure the conversation happens so they can make the most informed choice possible."

 

US Abortion bans and pregnancy-related care across physician specialties




JAMA Network Open





About The Study: 

In this qualitative study of the consequences of abortion bans across multiple medical specialties, abortion bans were associated with disrupted clinical care far beyond what is traditionally categorized as abortion, with treatment delays that endanger patients, undermined patient autonomy and physician-patient trust, and with new gatekeeping roles for physicians. These restrictions shifted medical decision-making from clinical judgment and patient values toward legal risk mitigation, with potential long-term consequences including exacerbation of health care inequities and compromised ability to provide safe and effective care for pregnant patients.



Corresponding Author: To contact the corresponding author, Sophia Landay, MD, email slanday@bidmc.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2026.19644)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article 

  https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19644?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062226

 


Mental health treatment disparities among transition-age youth with suicidal thoughts and behaviors



JAMA Pediatrics




About The Study: 

This nationally representative study showed that 1 in 8 transition-age youth (TAY) had suicidal thoughts and behaviors (STB), yet less than half of those with STB had any mental health care. Asian, Black, and Latine TAY experienced substantial access disparities, with treatment rates 14 to 21 percentage points lower than white peers. Despite all TAY having STB in the subsample in this study, the large service access differences suggest that structural barriers, rather than clinical appropriateness or patient preference alone, drive these inequities. 



Corresponding Author: To contact the corresponding author, Michael William Flores, PhD, MPH, email mwflores@cha.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamapediatrics.2026.2261)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article 

 https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2261?guestAccessKey=1619d29f-e9bd-4443-b0a8-df53cce63279&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062226